RxDoctor Payments DataLook up a doctor →

Jason Poon, MD

Neurology · Kirkland, WANPI 1417319658

Payments from drug & device makers

$933,873in general payments, 2019–2025

Across 365 payments — averaging $2558.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$767K
  • Biogen$90K
  • TG Therapeutics, Inc.$71K
  • EMD Serono, Inc.$1K
  • AbbVie$666
  • Bristol Myers Squibb$607
  • plus $4K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis62$767,052
Biogen2$90,024
TG Therapeutics, Inc.51$70,609
EMD Serono, Inc.35$1,232
AbbVie(2 entities)23$666
Bristol Myers Squibb48$607
Merz Pharmaceuticals, LLC22$553
Teva Pharmaceuticals USA, Inc.38$529
E.r. Squibb & Sons, L.L.C.3$373
Amgen7$221
Argenx US, Inc.3$162
CSL Behring7$158
Sanofi4$158
Johnson & Johnson5$143
Acorda Therapeutics, Inc2$125
Eisai Inc.5$121
Sunovion Pharmaceuticals Inc.1$121
Genentech USA, Inc.6$110
UCB, Inc.4$93
Acadia Pharmaceuticals Inc3$76
SK Life Science, Inc.3$75
Octapharma USA, Inc.3$59
Boston Scientific2$58
Pfizer2$49
Amneal Pharmaceuticals LLC3$48
Abbott1$43
Avanir Pharmaceuticals, Inc.2$40
Lundbeck LLC2$34
Neurelis, Inc.2$31
Ipsen Biopharmaceuticals, Inc1$29
Alnylam Pharmaceuticals Inc.1$28
Biohaven Pharmaceutical Holding Company Ltd.1$26
Neurocrine Biosciences, Inc.1$26
Takeda Pharmaceuticals U.S.A., Inc.1$22
Novo Nordisk1$22
Impel Pharmaceuticals Inc.1$21
Jazz Pharmaceuticals Inc.1$21
Cycle Pharmaceuticals Inc1$21
AstraZeneca1$20
Lilly USA, LLC1$19
Axsome Therapeutics, Inc.1$15
Banner Life Sciences, LLC1$15
Ultragenyx Pharmaceutical Inc.1$15

How this compares

$933,873 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington →

Medicare billing

Part B allowed, 2024
$34,647
Medicare patients
108
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Kirkland

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →